ORPHA:168829
Primary peritoneal carcinoma
Also known as: EOPPC · Extra-ovarian primary peritoneal carcinoma · PPC · Primary peritoneal serous carcinoma · Serous surface papillary carcinoma
Publications
4,812
Trials
536
Interventional, condition-specific
Researchers
1,350
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Primary peritoneal carcinoma (PPC) is a rare malignant tumor of the peritoneal cavity of extra-ovarian origin, clinically and histologically similar to advanced-stage serous ovarian carcinoma.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015686
- UMLS:C1514428
- NCIT:C40022
Additional Mondo synonyms (5)
primary peritoneal cancer · primary peritoneal carcinoma · primary peritoneal carcinoma (disease) · primary peritoneal serous carcinoma · serous surface papillary carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
4,812 matched papers (3,329 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
536 matched on ClinicalTrials.gov (73 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
4,812
4,812 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
4,812 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
3,329 in the last 10 years · low confidence
Phrase hits: 4,812 · MeSH hits: 0
Who's working on it?
1,350
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Aida T4 papers · 2026
Department of Obstetrics and Gynecology, Hachinohe Red Cross Hospital, Aomori 039-1104, Japan.
Papers in Europe PMC - 02Baba T4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 03Chiba Y4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 04Jo A4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 05Jonai N4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 06Kagabu M4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 07Kaido Y4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 08Mądry R4 papers · 2025
Oncological Gynaecology Department, Poznan University of Medical Sciences, 60-569 Poznań, Poland.
Papers in Europe PMC - 09Nagasawa T4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC - 10Sato S4 papers · 2026
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Yahaba 028-3695, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
536
interventional trials for this specific condition
536 interventional trials matched this specific condition name; 73 currently recruiting in our sample. 30 trials are registered for peritoneal carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
536 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.7th percentile).
low confidence · 99.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
536 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05128825·RECRUITING·A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer·Matched via name phrase
- NCT05659381·RECRUITING·Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Conditions: Stage III Ovarian Cancer · Stage IV Ovarian Cancer · Stage III Primary Peritoneal Cancer · Stage IV Primary Peritoneal Cancer·Matched via name phrase
- NCT07674615·NOT YET RECRUITING·IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
Conditions: Epithelial Ovarian Cancer · Fallopian Tube Cancers · Primary · Primary Peritoneal Carcinoma·Matched via name phrase
- NCT07480954·RECRUITING·Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Conditions: Epithelial Ovarian Cancer · Primary Peritoneal Carcinoma · Fallopian Tube Carcinoma · Recurrent or Refractory Disease After Standard Therapies·Matched via name phrase
- NCT07044349·NOT YET RECRUITING·Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer·Matched via name phrase
- NCT07532148·NOT YET RECRUITING·Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Cancer·Matched via name phrase
- NCT04575935·RECRUITING·Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Conditions: Advanced Ovarian Carcinoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Tumor · Fallopian Tube Serous Neoplasm·Matched via name phrase
- NCT05092373·RECRUITING·Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Conditions: Advanced Breast Carcinoma · Advanced Endometrial Carcinoma · Advanced Fallopian Tube Carcinoma · Advanced Hepatocellular Carcinoma·Matched via name phrase
- NCT06855706·RECRUITING·An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
Conditions: Endometrial Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma·Matched via name phrase
- NCT02637934·RECRUITING·Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Conditions: Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer·Matched via name phrase
- NCT03604315·RECRUITING·Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Conditions: Breast Carcinoma · Fallopian Tube Carcinoma · Ovarian Carcinoma · Primary Peritoneal Carcinoma·Matched via name phrase
- NCT07322094·RECRUITING·CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Conditions: FIGO Stage III and IV Ovarian Cancer · Fallopian Tube Cancers · Primary Peritoneal Cancer·Matched via name phrase
- NCT05564377·RECRUITING·Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Conditions: Advanced Malignant Solid Neoplasm · Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8 · Locally Advanced Malignant Solid Neoplasm·Matched via name phrase
- NCT05281471·RECRUITING·Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Conditions: Platinum-resistant Ovarian Cancer · Platinum-refractory Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer·Matched via name phrase
- NCT05737303·RECRUITING·Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Conditions: Epithelial Ovarian Carcinoma Stage III · Epithelial Ovarian Carcinoma Stage IV · Fallopian Tube Carcinoma Stage III · Fallopian Tube Carcinoma Stage IV·Matched via name phrase
Broader category: peritoneal carcinoma
30
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06290193·RECRUITING·Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Conditions: Ovarian Cancer · Fallopian Tube Carcinoma · Ovarian Carcinoma · Peritoneal Carcinoma·Matched via name phrase
- NCT06846424·NOT YET RECRUITING·SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Conditions: Ovarian Cancer · Fallopian Tube Carcinoma · Peritoneal Carcinoma·Matched via name phrase
- NCT06743867·RECRUITING·The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic Adenocarcinoma
Conditions: Peritoneal Carcinoma Metastatic·Matched via name phrase
- NCT04684459·RECRUITING·Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
Conditions: Peritoneal Carcinoma Metastatic · Pleural Effusion, Malignant · HER2 Positive Malignancies·Matched via name phrase
- NCT07001592·RECRUITING·Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Conditions: Gastric Neoplasms · Esophageal Cancer · Liver Cancer · Liver Metastasis·Matched via name phrase
Observational and natural-history studies
44 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06295965·RECRUITING·Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Conditions: Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma · Recurrent Malignant Solid Neoplasm·Matched via name phrase
- NCT07667192·RECRUITING·Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
Conditions: Recurrent Gynecologic Cancer · Recurrent Uterine Cancer · Recurrent Cervical Cancer · Recurrent Vaginal Cancer·Matched via name phrase
- NCT05574673·RECRUITING·Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Conditions: Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer·Matched via name phrase
- NCT07269574·NOT YET RECRUITING·Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance
Conditions: Ovarian Cancer · Fallopian Tube Cancers · Primary Peritoneal Carcinoma · High-grade Serous Ovarian Cancer·Matched via name phrase
- NCT00488878·RECRUITING·Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Conditions: Low Grade Ovarian Serous Adenocarcinoma · Malignant Ovarian Neoplasm · Ovarian Carcinoma · Primary Peritoneal Carcinoma·Matched via name phrase
- NCT07690332·NOT YET RECRUITING·A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α(FRα)
Conditions: Ovarian Cancer · Fallopian Tube Cancers · Primary Peritoneal Cancer·Matched via name phrase
- NCT06010667·NOT YET RECRUITING·A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Conditions: Epithelial Ovarian Cancer·Matched via name phrase
- NCT07407062·NOT YET RECRUITING·A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy
Conditions: Cancer - Ovarian·Matched via name phrase
- NCT07687602·NOT YET RECRUITING·A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
Conditions: Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer · Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer · Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Primary peritoneal carcinoma" OR "EOPPC" OR "Extra-ovarian primary peritoneal carcinoma" OR "Primary peritoneal serous carcinoma" OR "Serous surface papillary carcinoma" OR "primary peritoneal cancer" OR "primary peritoneal carcinoma (disease)"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Primary peritoneal carcinoma" OR "EOPPC" OR "Extra-ovarian primary peritoneal carcinoma" OR "Primary peritoneal serous carcinoma" OR "Serous surface papillary carcinoma" OR "primary peritoneal cancer" OR "primary peritoneal carcinoma (disease)"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 536 interventional · 44 observational · 1 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"peritoneal carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: PPC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (4812) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T08:31:31.271Z
